Rhanda Lopez

Rhanda Lopez serves as a key procurement professional within the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), supporting the agency’s mission to accelerate the translation of scientific discoveries into clinical applications. She manages complex acquisitions for advanced laboratory technologies, high-throughput screening systems, and precision metabolite synthesis platforms, ensuring that NCATS maintains cutting-edge capabilities in translational research. Her portfolio centers on technical services and specialized instrumentation critical to rapid biological candidate evaluation, including automated analytical systems and tissue chip platforms. Lopez plays a pivotal role in aligning procurement strategy with NCATS’s innovation-driven objectives, facilitating timely access to next-generation research tools. Lopez collaborates with a diverse range of vendors specializing in analytical instrumentation, biological manufacturing, and independent testing laboratories. Her contracting patterns reflect strong engagement with firms capable of delivering custom-built lab systems, validated assay services, and automated data analytics platforms. While no single contractor dominates her portfolio, she consistently partners with technical specialists who demonstrate expertise in GMP-compliant processes, regulatory-grade validation, and scalable biomanufacturing workflows. Her approach emphasizes vendor capability over volume, prioritizing technical fit and scientific rigor in contractor selection. Lopez’s procurement activity is entirely non-set-aside, with 100% of acquisitions conducted under full and open competition. This reflects NCATS’s operational need for specialized, non-redundant capabilities that may not be widely available among small or socioeconomically disadvantaged businesses. While she does not prioritize 8(a), HUBZone, or SDVOSB set-asides, her contracting decisions are grounded in technical merit and mission-critical performance requirements rather than socioeconomic preferences. Her primary procurement focus lies in NAICS 334516 (Analytical Laboratory Instrument Manufacturing), 325414 (Biological Product Manufacturing), and 541380 (Testing Laboratories and Services). She routinely acquires high-precision analytical instruments, recombinant protein synthesis systems, and certified reference material production services. Her domain expertise spans translational biology, metabolomics, and automated high-content screening, ensuring that acquired technologies meet the rigorous standards required for preclinical validation and drug development pipelines.